Pancreatic Cancer Research

ResearcherXuzhou Medical CollegeActive in the last 2 years

Chao Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2219-5203; OpenAlex author ID A5001203824. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. A Naples prognostic score-based nomogram enhances perioperative risk stratification for resected pancreatic cancer. Co-author DOI 10.1080/14796694.2026.2687698↗
  2. Research on precision treatment of pancreatic cancer targeted by antibody-drug conjugates. Co-author DOI 10.5582/bst.2025.01271↗
  3. Targeting TNK2/ACK1 reverses the immunosuppressive tumor microenvironment and synergizes with immunochemotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-025-67197-3↗
  4. CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism. Co-author DOI 10.1002/advs.202206335↗
  5. Identification of key pharmacological components and targets for Aidi injection in the treatment of pancreatic cancer by UPLC-MS, network pharmacology, and in … Co-author DOI 10.1186/s13020-023-00710-2↗
  6. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endopl… First author DOI 10.1186/s13046-023-02814-x↗
  7. A novel strategy to reveal clinical advantages and molecular mechanism of aidi injection in the treatment of pancreatic cancer based on network meta-analysis a… Co-author DOI 10.1016/j.jep.2021.114852↗
  8. A network pharmacology approach to reveal the pharmacological targets and biological mechanism of compound kushen injection for treating pancreatic cancer base… Co-author DOI 10.1186/s13020-021-00534-y↗
  9. Insulin-like growth factor 1-induced enolase 2 deacetylation by HDAC3 promotes metastasis of pancreatic cancer. First author DOI 10.1038/s41392-020-0146-6↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weishuai Liu · 4 shared papers, 2023–2026 · strength 0.84
  2. Jihui Hao · 4 shared papers, 2023–2026 · strength 0.84
  3. Xinyue Liu · 2 shared papers, 2025–2026 · strength 0.54
  4. Jun Yang · 1 shared paper, 2026 · strength 0.50
  5. Bole Tian · 1 shared paper, 2026 · strength 0.50
  6. Jiarui Wu · 3 shared papers, 2021–2023 · strength 0.40
  7. Yongjie Xie · 2 shared papers, 2023–2025 · strength 0.34
  8. Chongbiao Huang · 2 shared papers, 2023–2025 · strength 0.33
  9. Shengnan Li · 2 shared papers, 2023–2025 · strength 0.33
  10. Haojia Wang · 2 shared papers, 2022–2023 · strength 0.29
  11. Song Gao · 1 shared paper, 2025 · strength 0.18
  12. Yiping Zou · 1 shared paper, 2025 · strength 0.18
  13. Jun Yu · 1 shared paper, 2025 · strength 0.18
  14. Yukuan Feng · 1 shared paper, 2025 · strength 0.18
  15. Chao Yang · 1 shared paper, 2025 · strength 0.18
  16. Chunhua She · 1 shared paper, 2023 · strength 0.16
  17. Chao Xu · 1 shared paper, 2023 · strength 0.16
  18. Xiuchao Wang · 1 shared paper, 2023 · strength 0.16
  19. Bo Tang · 1 shared paper, 2023 · strength 0.14
  20. Peng Xie · 1 shared paper, 2023 · strength 0.14
  21. Xiaozhou Yu · 1 shared paper, 2023 · strength 0.14
  22. Jiaqi Huang · 1 shared paper, 2021 · strength 0.11
  23. Feng Yang · 1 shared paper, 2020 · strength 0.09
  24. Qiongzhu Dong · 1 shared paper, 2020 · strength 0.09
  25. Beiyuan Hu · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.